Form Type and Date: This is an 8-K Current Report filed by IDEXX Laboratories Inc on August 4, 2026, reporting events as of that same date. Item 2.02 - Results of Operations and Financial Condition: The filing indicates disclosure of results of operations and financial condition, though the specific financial results and performance metrics are not detailed in the header sections provided. Item…

Our analysis rates this filing BULLISH. IDEXX Laboratories demonstrates exceptionally strong operational performance with raised guidance across all key metrics despite macro headwinds. Q2 results show 18% EPS growth with 140 bps gross margin expansion, indicating earnings are growing significantly…

Concern level: LOW (1.5/10). Key factors: Foreign exchange headwind of $15M revenue and $0.05 EPS impact for 2026 represents macro currency exposure; Capital instrument revenue declined 19-20% organically due to lap of prior-year broad availability of IDEXX inVue Dx; Cyclical nature of capital equipment sales creates revenue volatility in diagnostics segment.

Notable risk changes: Raised 2026 revenue guidance midpoint by $5M to $4,700-$4,745M (9.1%-10.3% growth), reflecting strong CAG Diagnostics recurring revenue performance; Increased 2026 EPS outlook to $14.69-$14.94 (12%-14% reported growth), up $0.14 at midpoint from operational performance despite $15M FX headwind; Narrowed full-year operating margin guidance to 32.3%-32.5%, projecting 70-90 basis points expansion,…